Moreover, there is a lack of specificity with respect to targeting cancer cells versus normal cells, unless the tumours have already been sensitised to PARP-1 inhibition due to a deficient DNA repair system or specific genetic background [41]. The gene discussed is PARP1; the disease is neoplasm.